Since dual inhibition targeting EGFR and YAP could provide better therapeutic effect than single inhibition of each 12, we set out to explore if the combination of YAP and EGFR inhibition reverses chemotherapy resistance in colorectal cancer. This evidence concerns the gene EGFR and colorectal cancer.